BioMed Research International / 2014 / Article / Tab 1

Research Article

Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

Table 1

Patient characteristics at the time of the coronary event.

CharacteristicsHIV-infected patients ()

Age, years (median [IQR])48 (40, 57)
Patients > 50 years (%)38.3
Gender (male) (%)86.1
Body mass index >25 (%)9.8
Men who have sex with men (%)38.6
HCV coinfection (%)4.9
HBV coinfection (%)12.3

HIV-related characteristics
Time since diagnosis of HIV-infection, years (median [IQR])14.9 (10.4, 19.2)
Cumulative exposure to antiretrovirals (median [IQR])12.7 (9.3, 16.2)
 Cumulative exposure to PIs (median [IQR]) 5 (0.7, 8)
 Cumulative exposure to NNRTIs (median [IQR]) 3 (0.1, 7)
 Cumulative exposure to abacavir (median [IQR])2 (0, 11)
CD4 cells count/µL (median [IQR])224 (89, 422)
HIV-RNA ≤ 400 copies/mL (median [IQR])46 (56.8%)
Lipodystrophy (including lipoatrophy) (%)36.1

Cardiovascular risk factors
Family history of coronary heart disease (%)17 (20.5%)
Smoking (%)36 (44%)
 Cumulative exposure to tobacco smoke, years (mean [SD])23 (9.4)
Hypertension (%)49 (60.5)
 *Use of antihypertensive treatment (%)43 (87.8)
Diabetes mellitus (%)13 (16)
 *Use of antidiabetic treatment (%)10 (76.9)
Dyslipidemia (%)44 (48.1)
 Serum total cholesterol, mg/dL (median [IQR])182 (152, 230)
 Serum HDL-cholesterol, mg/dL (median [IQR])42 (35, 52)
 Serum LDL-cholesterol, mg/dL (median, [IQR])104 (98, 194)
 Serum triglycerides, mg/dL (median, [IQR])168 (106, 248)
 *Use of lipid-lowering agents (%)39 (88.6)

Data was reported as median and interquartile range [IQR].
*Percentages of patients using antihypertensive drugs, antidiabetic treatment or lipid-lowering agents were calculated considering the number of patients receiving that treatment with respect to those who required treatment (considering target parameters according to the guidelines).